Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer

Annals of Oncology

Volumn 20, Issue 5, 2009, Pages 965-

  Serrate, C ^a   Loriot, Y ^a   De La Motte Rouge, T ^a   Gross goupil, M ^a   Massard, C ^a   Escudier, B ^a   Bossi, A ^a   Fizazi, K ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANDROGEN; DIETHYLSTILBESTROL; DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER PAIN; CANCER SURVIVAL; CLINICAL TRIAL; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; LOW DRUG DOSE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 65549090179     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp112     Document Type: Article

References (6)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
3. Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-4571.
4. Danila DC, Rathkopf DE, Morris JM et al. Abiraterone acetate and prednisone in patients with progressive metastatic castration resistant prostate cancer after failure of docetaxel-based chemotherapy. J Clin Oncol 2008; 26: (Abstr 5019).
5. Fizazi K, Le Maitre A, Hudes G et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: A meta-analysis of individual patient data. Lancet Oncol 2007; 8: 994-1000.
6. Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001; 58: 108-113.